MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Pharmaceutical Development and Clinical Trials (Facts & Figures)
2018: The top 15 pharma companies by 2017 revenue
Gilead Sciences, Inc. (NASDAQ: GILD)*
Organization & Developments: Gilead
Parents
Gilead Sciences, Inc. (NASDAQ: GILD)*
Children
*Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide)
*Developments: Gilead
*Developments: Gilead (Archives 2010-2015)
*Developments: Gilead (Archives 2016)
*Developments: Gilead (Archives 2017)
*Developments: Gilead (Archives 2018)
*Developments: Gilead (Archives 2019-2022)
*Discovery, development, and commercialization of treatments to fight bacterial, fungal and viral infection
*Gilead: Brands
*HIV Drug Franchise
*Operations in North America, Europe and Australia
*Organization: Gilead
*Tamiflu
*The Pharmasett deal is expected to speed development of treatments for hepatitis C, an area where Pharmasset expanded a trial of an oral treatment
2023: Gilead After Q3 2023 Earnings: Grading Its Top Cancer Acquisition_ seekingalpha.com
2023: Gilead Sciences Is Building A Diversified Portfolio_ seekingalpha.com
2023: Gilead Sciences: A Healthy Buy With Solid Dividend
2023: Gilead Sciences: A Mixed First Quarter_ seekingalpha.com
2023: Gilead Sciences: Mixed Signals, Again
2023: Gilead Sciences: Searching For A Catalyst
2023: Gilead Sciences: Slow Progress, But Progress Altogether (NASDAQ:GILD)
2024: ‘Gamechanger’ HIV prevention drug to be made available cheaply in 120 countries
2024: Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
2024: Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation_ seekingalpha.com
2024: Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
2024: Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech
2024: Gilead bets on ‘trispecifics’ in latest cancer drug deal
2024: Gilead Sciences Finally Starts Succeeding
2024: Gilead Sciences: 2024 Catalysts Should Drive Growth And Change In Sentiment
2024: Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise
2024: Gilead Sciences: Approaching Overvalued_seekingalpha.com
2024: Gilead Sciences: Finally Some Real Momentum
2024: Gilead Sciences: Realizing Financial Projections Is Key
2024: Gilead Sciences: Strategic Gains From Lenacapavir And Trodelvy Justify A Buy Rating
2024: Gilead Sciences: The Sky Is Not Falling
2024: Gilead Sciences: The Upcycle Is Just Getting Started
2024: Gilead Sciences' SWOT analysis: lenacapavir success fuels HIV stock growth
2024: Gilead Stock Plunges More Than 10% After Failed Lung Cancer Treatment Tria
2024: Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda
2024: Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure
2024: Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure
2024: Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution
2024: Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?
2024: New Drug Provides Total Protection From H.I.V. in Trial of Young African Women_ nytimes
2024: Science Breakthrough-2024_An injectable HIV drug with a novel mechanism shows remarkable ability to prevent infection
2024: Twice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill
2025: #5. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Gilead Sciences 2024 Sales: $13.423 billion 2023 Sales: $11.850 billion % Change: +13.3%
2025: A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
2025: From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave
2025: Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
2025: Gilead Sciences Is Overvalued Now (Rating Downgrade)
2025: Gilead Sciences: HIV Leadership Outshines Decline In COVID-19 Drug Sales
2025: Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
2025: Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
2025: Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
2025: Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win
2025: Gilead Sciences' Best Days May Be Ahead - Here's Why
2025: Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
2025: Gilead: Strong Sales Growth Remains With Veklury And Beyond
2025: Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It?
2025: Groups push for cheap generic versions of HIV prevention drug
2025: Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV Prevention Option Offering 6 Months of Protection
2026: #3 Anito-cel, Company: Gilead Sciences/Arcellx Used for: Multiple myeloma Est. 2032 sales: $2.5 billion
Jumps
*Key People: Gilead
Finance & Acquisitions: Gilead